- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05439655
Acute Recording of Stereotyped High-Frequency Oscillations
Acute Recording of Stereotyped High-Frequency Oscillations With a Closed-Loop Brain Interchange System in Drug-Resistant Epilepsy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
High-frequency oscillations (HFOs) of intracranial EEG (iEEG) have the potential to identify the surgical resection area/seizure onset zone (SOZ) in patients with drug-resistant epilepsy. However, multiple reports indicate that HFOs can be generated not only by epileptic cerebral tissue but also by non-epileptic sites often including eloquent regions such as motor, visual, and language cortices. In this project, the initial evidence of a recurrent waveform pattern is presented that may be sufficient to distinguish pathological HFOs from physiological ones. Specifically, the investigators show that the SOZ repeatedly generates sets of stereotypical HFOs with similar waveform morphology whereas the events recorded from out of SOZ were irregular. This morphological pattern served as a robust neurobiomarker to isolate SOZ from other brain areas in multiple patients consistently. While these promising preliminary results are in place, the functional utility of stereotyped HFOs in a closed-loop seizure control system remains unknown. As of today, not much is known whether the stereotyped HFOs generated by the SOZ can be detected with an implantable system. If this can be achieved, then HFOs can be strategically translated as a neurobiomarker into closed-loop seizure control applications. The investigators hypothesize that pathologic stereotyped HFOs can be captured with the implantable Brain Interchange (BIC) system of CorTec and spatial topography of these events can be utilized by the implantable system to deliver targeted electrical stimulation to achieve seizure control. Using an acute setup within the epilepsy monitoring unit (EMU), this project will investigate the feasibility of capturing stereotyped HFO events using the new BIC system and compare the detection results to those obtained with the commercially available amplifier (Aim-1). If the first phase (Aim-1) of the study becomes successful, later in the second phase (Aim-2), once again in the EMU, the investigators will deliver targeted electrical stimulation to those brain sites associated with stereotyped HFOs using the BIC.
During the entire study, the BIC system will not be implanted but used externally to assess the neural data through externalized electrodes and then deliver closed-loop stimulation. If the outcomes of the research in an acute setting become successful, the investigators will execute a clinical trial and run our methods with the implanted BIC system in a chronic ambulatory setting.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Texas
-
Houston, Texas, United States, 77030-3498
- Baylor College of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- patients with medically refractory epilepsy, who have been deemed appropriate candidates for intracranial EEG monitoring
- Adult men and women (18≤ age <70 years)
- children (3≤ age <18 years)
- includes women and minorities
Exclusion Criteria:
- Subjects will be excluded if their condition makes them unable to continue with recordings.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Epilepsy
patients with drug resistant epilepsy undergoing a surgical evaluation in the epilepsy monitoring unit
|
The CorTec Brain Interchange (BIC) is an implantable system with sensing and stimulation capability dedicated to promoting brain computer interface and closed-loop neuromodulation research.
It is an externally powered implant which can provide neural data to a nearby computing station (communication unit connected to a personal computer) continuously.
In return, computing station controls the implant e.g. for generating therapeutic electrical stimulation to the brain.
It is expected that BIC will catalyze translational applications of electroceuticals in human subject by making the neural data immediately available as well as permit the investigation of novel closed-loop neuromodulation applications.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Robustness in Data Transmission
Time Frame: Over 24 hours within the first year of project
|
Outcome-1 will quantify the feasibility of robust data recording and transmission with the BIC system in the epilepsy monitoring unit (EMU).
The investigators will develop software tools to communicate with the BIC directly from MATLAB and Simulink.
The incoming data from the implantable system will be visualized with gHIsys, the high-speed data processing libraries of gTec.
At the end of the first year, in the epilepsy monitoring unit (EMU), the investigators will test the feasibility of recoding iEEG data from 2 patients continuously over 24 hours with less than <5% data loss.
The BIC system will not be implanted but used externally to record the neural data.
The research team will also test to record iEEG/ECoG data simultaneously with 2 BIC units to be ready for those cases where the number of recording channels are larger than =>32 and <=64.
At this stage Outcome-1 is only related to the device feasibility (robust data transmission) not health related outcome.
|
Over 24 hours within the first year of project
|
|
Feasibility of Detection of Stereotyped HFOs
Time Frame: Within the first 3 years of the project
|
Outcome-2 will test the feasibility of capturing stereotyped HFO (sHFO) with the BIC system in the EMU setting.
Once the feasibility of robust data transmission as listed in (Outcome-1) is tested, the neural activity will be recorded over 24 hours using the BIC system from 10 patients.
The hardware will not be implanted but used externally to record the neural data.
Then, the research team will compare whether the sHFO detection and SOZ localization accuracy is significantly different between the BIC and FDA approved amplifier.
If the investigators can detect stereotyped HFOs with a rate not less than 75% of FDA approved clinical amplifier and predict the SOZ in 8/10 patients, then the research team will move to the second phase of the project to test Outcome-3.
Outcome-2 tests the feasibility of capturing relevant neural events with the external BIC system and compares the recording quality to the FDA approved amplifiers.
Outcome-2 does not test any health-related outcome.
|
Within the first 3 years of the project
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 23-008859
- 1UH3NS117944-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Intracranial EEG + ECoG recorded from patients with epilepsy will be shared. The electrical signs of neural activity will be collected in the EMU for 24hrs. One stream of data will be digitized at 1kHz with 16bit resolution with the BIC system and the other stream with least a 2 kHz sampling frequency to capture HFOs reaching up to 500Hz.
All collected data will be de-identified prior to data exchange. Patient data will be provided in a coded format that protects patient identities but will contain diagnosis (signs/symptoms), interventions including technical observations, diagnostic tests/results, and patient outcomes.
Information about the recording device including device serial numbers, device model numbers, date of the event, and country/state of the event will be annotated with the data.
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsy
-
NaviFUS CorporationTaipei Veterans General Hospital, TaiwanCompletedDrug Resistant Epilepsy | Epilepsy, Drug Resistant | Intractable Epilepsy | Refractory Epilepsy | Drug Refractory Epilepsy | Epilepsy, Drug Refractory | Epilepsy, Intractable | Medication Resistant EpilepsyTaiwan
-
Great Ormond Street Hospital for Children NHS Foundation...Active, not recruitingEpilepsies, Partial | Intractable Epilepsy | Focal Epilepsy | Refractory Epilepsy | Epilepsy Intractable | Epilepsy in Children | Epilepsy, FocalUnited Kingdom
-
University of British ColumbiaTerminatedJuvenile Myoclonic Epilepsy | Childhood Absence Epilepsy | Juvenile Absence EpilepsyCanada
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
Oslo University HospitalCompletedEpilepsy | Generalized Epilepsy | Focal EpilepsyNorway
-
UCB Pharma SACompletedEpilepsy, Tonic-clonicPoland, Sweden, Hungary, Czechia
-
UCB PharmaCompletedEpilepsy, Tonic-clonic
-
Institute of Child HealthGreat Ormond Street Hospital for Children NHS Foundation TrustNot yet recruitingEpilepsy Intractable | Epilepsy in Children
-
University Hospital, LilleCompletedFocal Epilepsy | Epilepsy IntractableFrance
-
Massachusetts General HospitalBoston University; National Institute of Neurological Disorders and Stroke...CompletedEpilepsy | Epilepsy; Seizure | Rolandic Epilepsy | Rolandic Epilepsy, Benign | Centrotemporal Epilepsy | Centrotemporal; EEG Spikes, Epilepsy of ChildhoodUnited States
Clinical Trials on Brain Interchange System
-
Mayo ClinicBaylor College of Medicine; National Institute of Neurological Disorders and... and other collaboratorsNot yet recruiting
-
University of WashingtonNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingStroke, IschemicUnited States
-
Abbott Medical DevicesTerminatedDepressive Disorder, Major | Unipolar DepressionUnited States, Canada, United Kingdom
-
Butler HospitalMedtronicCompletedObsessive-Compulsive DisorderUnited States
-
Boston Scientific CorporationCompletedParkinson's DiseaseUnited States
-
Butler HospitalMedtronicCompleted
-
Ruijin HospitalUnknownObsessive-Compulsive DisorderChina
-
Newcastle-upon-Tyne Hospitals NHS TrustMedtronic; Dystonia EuropeRecruitingDystonia | Dystonia, Primary | Dystonia, FocalUnited Kingdom
-
Abbott Medical DevicesCompletedDepressive Disorder, MajorIsrael, France, United Kingdom
-
University of FloridaCompleted